ATI-450 ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2
106	クリオピリン関連周期熱症候群	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05279417 (ClinicalTrials.gov)	February 2, 2022	18/2/2022	ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA	ATI-450Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA Who Have Had a ...	Rheumatoid Arthritis	Drug: ATI-45050mg oral tablet BID;Drug: Placebo oral tablet;Drug: Methotrexate;Drug: ATI-45020mg ora ...	Aclaris Therapeutics, Inc.	NULL	Recruiting	18 Years	75 Years	All	240	Phase 2	United States;Czechia;Poland
2	NCT04247815 (ClinicalTrials.gov)	March 16, 2020	16/1/2020	Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA	A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-c ...	Rheumatoid Arthritis	Drug: ATI-450;Drug: Placebo oral tablet;Drug: Methotrexate	Aclaris Therapeutics, Inc.	NULL	Completed	18 Years	70 Years	All	19	Phase 2	United States

臨床試験数 : 42 / 薬物数 : 24 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04524858 (ClinicalTrials.gov)	October 23, 2020	19/8/2020	Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)	A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450for the Ma ...	Cryopyrin-Associated Periodic Syndrome	Drug: ATI-450	Aclaris Therapeutics, Inc.	NULL	Terminated	18 Years	N/A	All	1	Phase 2	United States